4.8 Article

In vivo fate of liposomes after subconjunctival ocular delivery

Journal

JOURNAL OF CONTROLLED RELEASE
Volume 329, Issue -, Pages 162-174

Publisher

ELSEVIER
DOI: 10.1016/j.jconrel.2020.11.053

Keywords

Liposomes; Ocular delivery; Biodistribution; In vivo imaging; Drug delivery systems

Funding

  1. NTU-Northwestern Institute for Nanomedicine (NNIN)
  2. Singapore National Research Foundation [AG/CIV/GC70-C/NRF/2013/2]

Ask authors/readers for more resources

Subconjunctival administration of nanocarriers can enhance drug bioavailability in specific parts of the eye by overcoming blood-ocular barriers. Different characteristics of liposomes (charge, size, cholesterol content, and lipid saturation) influence their distribution in ocular and corporeal tissues. Optimizing liposome design is necessary to control the temporal and spatial bioavailability and clearance of nanocarriers from the eye, improving the efficacy and safety of ocular therapeutics.
Subconjunctival administration of nanocarriers presents an alternative drug delivery strategy to overcome blood-ocular barriers to enhance drug bioavailability to specific parts of the eye. Using fiberoptic Confocal Laser Microendoscopy (CLM) and radiotracing, we describe the effects of charge, size, cholesterol content and lipid saturation on the ocular and corporal distribution of liposome nanocarriers in live mouse models. Positively charged or large (>250 nm) liposomes exhibit sustained ocular residence times in and around the injection site; cholesterol loading slows down this clearance, whereas lipid saturation accelerates clearance. Neutral, negatively charged, or smaller sized liposomes distribute to the limbus, rich in stem cells and blood capillaries. Differential lymphatic and systemic clearance from the eye to corporeal tissues was also observed across formulations. These results demonstrate the need to optimize liposome design for control over temporal and spatial nanocarrier bioavailability and clearance from the eye for improved efficacy and safety of ocular therapeutics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available